Q2 2025 · 13F-HR
Logos Global Management LPholdings as filed
Filed 2025-08-14 · accession 0001172661-25-003284
$903.8M
Reported value
51
Positions
2025-06-30
Period end
The Brief · Logos Global Management LP · Q2 2025
AI · grounded in 13F
Logos Global Management LP established a new position in XBI valued at $82.9M. The fund also initiated new stakes in IDYA for $70.3M and AKRO for $64M. Additional new positions include RVMD at $62.5M and JAZZ at $47.8M. The fund ended the period with 49 positions and total AUM of $903.8M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 78464A870 | XBI | SPDR SERIES TRUST | $82.9M | 9.18% | 1,000,000 | CALL | SOLE |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $70.3M | 7.78% | 3,345,000 | Common | SOLE |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $64.0M | 7.08% | 1,200,000 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $62.5M | 6.92% | 1,700,000 | Common | SOLE |
| G50871105 | JAZZ | JAZZ PHARMACEUTICALS PLC | $47.8M | 5.28% | 450,000 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $37.1M | 4.10% | 700,000 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $27.0M | 2.99% | 950,000 | Common | SOLE |
| 492327101 | KROS | KEROS THERAPEUTICS INC | $26.7M | 2.95% | 2,000,000 | Common | SOLE |
| 881624209 | TEVA | TEVA PHARMACEUTICAL INDS LTD | $25.1M | 2.78% | 1,500,000 | CALL | SOLE |
| 09062X103 | BIIB | BIOGEN INC | $25.1M | 2.78% | 200,000 | Common | SOLE |
| 91307C102 | UTHR | UNITED THERAPEUTICS CORP DEL | $24.4M | 2.70% | 85,000 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS INC | $24.3M | 2.69% | 3,300,000 | Common | SOLE |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $23.1M | 2.56% | 1,000,000 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $20.4M | 2.26% | 2,200,000 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $19.1M | 2.11% | 15,000,000 | Common | SOLE |
| 64125C109 | NBIX | NEUROCRINE BIOSCIENCES INC | $18.9M | 2.09% | 150,000 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $18.1M | 2.00% | 1,900,000 | Common | SOLE |
| 45258D105 | IMCR | IMMUNOCORE HLDGS PLC | $18.0M | 2.00% | 575,000 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $17.6M | 1.95% | 850,000 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $17.3M | 1.92% | 1,000,000 | CALL | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $15.1M | 1.67% | 50,000 | Common | SOLE |
| 25056L103 | DSGN | DESIGN THERAPEUTICS INC | $14.2M | 1.57% | 4,217,627 | Common | SOLE |
| 501147102 | KRYS | KRYSTAL BIOTECH INC | $13.7M | 1.52% | 100,000 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $13.7M | 1.51% | 3,208,875 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $12.2M | 1.35% | 600,000 | Common | SOLE |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $11.6M | 1.28% | 500,000 | CALL | SOLE |
| 04335A105 | ARVN | ARVINAS INC | $11.0M | 1.22% | 1,500,000 | CALL | SOLE |
| G1110E107 | BHVN | BIOHAVEN LTD | $9.9M | 1.09% | 700,000 | Common | SOLE |
| 98401F105 | XNCR | XENCOR INC | $9.8M | 1.09% | 1,250,000 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $9.5M | 1.05% | 225,000 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $9.4M | 1.04% | 200,000 | Common | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $9.3M | 1.02% | 190,000 | Common | SOLE |
| G2545C104 | CBIO | CRESCENT BIOPHARMA INC. | $8.9M | 0.99% | 553,686 | Common | SOLE |
| 52490G102 | LEGN | LEGEND BIOTECH CORP | $8.9M | 0.98% | 250,000 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $8.2M | 0.91% | 130,000 | Common | SOLE |
| 578784100 | MAZE | MAZE THERAPEUTICS INC | $7.5M | 0.83% | 611,914 | Common | SOLE |
| 517125100 | LRMR | LARIMAR THERAPEUTICS INC | $7.2M | 0.80% | 2,500,000 | CALL | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $7.0M | 0.78% | 350,000 | Common | SOLE |
| 008064206 | JBIO | JADE BIOSCIENCES INC | $6.2M | 0.69% | 625,000 | Common | SOLE |
| 03589W102 | ANNX | ANNEXON INC | $5.8M | 0.64% | 2,410,000 | Common | SOLE |
| 59267L107 | — | METSERA INC | $5.7M | 0.63% | 200,000 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $4.6M | 0.51% | 850,000 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $4.4M | 0.49% | 275,000 | Common | SOLE |
| 92337C203 | VSTM | VERASTEM INC | $4.2M | 0.46% | 1,000,000 | Common | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS INC | $3.8M | 0.42% | 700,000 | Common | SOLE |
| 055477103 | BCAX | BICARA THERAPEUTICS INC | $3.7M | 0.41% | 400,000 | Common | SOLE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $2.6M | 0.29% | 1,850,000 | Common | SOLE |
| 75383L102 | RAPP | RAPPORT THERAPEUTICS INC | $2.4M | 0.26% | 208,910 | Common | SOLE |
| 90466Y202 | UNCY | UNICYCIVE THERAPEUTICS INC | $2.3M | 0.25% | 473,562 | Common | SOLE |
| 81734D104 | SEPN | SEPTERNA INC | $1.2M | 0.13% | 109,202 | Common | SOLE |
| 67080N119 | NUVB/WS | NUVATION BIO INC | $17,993 | 0.00% | 66,666 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.